# Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients

> **NCT05167513** · PHASE4 · COMPLETED · sponsor: **Getz Pharma** · enrollment: 188 (actual)

## Conditions studied

- Quality of Life
- Type 2 Diabetes
- Metformin+Sitagliptin

## Interventions

- **DRUG:** Metformin / Sitagliptin Oral Tablet

## Key facts

- **NCT ID:** NCT05167513
- **Lead sponsor:** Getz Pharma
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-01-01
- **Primary completion:** 2022-04-28
- **Final completion:** 2022-04-28
- **Target enrollment:** 188 (ACTUAL)
- **Last updated:** 2022-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167513

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167513, "Monitoring Parameters Beyond Glycemic Control: Impact of Sitagliptin on Quality of Life in Type 2 Diabetes Patients". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05167513. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*